Mg Of Meloxicam Research Articles

Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam

Purpose To assess the risk of serious gastrointestinal and thromboembolic complications with approved doses of meloxicam. Methods We pooled data from clinical trials of meloxicam at doses of 7.5 or 15 mg/d. A blinded gastrointestinal adjudication committee used prespecified criteria to identify gastric or duodenal perforation, gastric outlet obstruction, or hemodynamically important upper gastrointestinal bleeding. For analysis of thromboembolic complications, investigator-reported events were analyzed without adjudication. Results We analyzed data from 24,196 patients from 28 trials, most of whom had been followed for up to 60 days. Of these patients, 13,118 received meloxicam (10,158 received a daily dose of 7.5 mg and 2960 received 15 mg), 5283 were treated with diclofenac 100 mg, 181 received diclofenac 150 mg, 5371 were treated with piroxicam 20 mg, and 243 received naproxen 500 mg twice daily. Patients who received 7.5 mg of meloxicam daily had a 0.03% risk of serious upper gastrointestinal events, which was significantly lower than the risk in those who received diclofenac, naproxen, or piroxicam ( P <0.02). With the 15 mg daily dose of meloxicam, this risk was significantly different only when compared with piroxicam ( P = 0.03). The risk of thromboembolic events in patients treated with meloxicam at either dose was lower than with diclofenac, but similar to that observed with piroxicam and naproxen. Conclusion This pooled analysis of 24,196 patients demonstrates that meloxicam has a favorable gastrointestinal and thromboembolic safety profile. However, only a small number of patients were followed for more than 60 days, and meaningful comparisons were not possible in this subgroup.

Poster 112: The influence of a combination of infrared light with transcutaneous electric nerve stimulation in patients with cervical symptoms of ankylosing spondylitis.

Objective: To study the advantages of a home treatment combination of infrared (IR) light with transcutaneous electric nerve stimulation (TENS) over the classic approach of nonsteriodal anti-inflammatory drugs (NSAIDs) in treating ankylosing spondylitis (AS). Design: Prospective randomized follow-up study. Setting: Academic medical center. Participants: Patients were randomized into 2 groups (20 each). All were men, ages 30 to 40 years old, with cervical symptoms of AS. Interventions: Range of motion of the cervical spine and presence of pain in the neck were evaluated in each group. Patients in both groups underwent kinesitherapy during 2 weeks. Also, group 1 took NSAIDs (7.5mg of meloxicam twice a day), while group 2 had TENS (30min) applied with IR lamp 300W (20min) over the cervical region every morning. Main Outcome Measures: Pain decrease and movement increase. Results: After 2 weeks, in group 1, 60% of the patients experienced a reduction in pain, while 25% experienced an increased amplitude of neck movements. In group 2, 40% experienced a reduction in pain and 75% had a significant increase in neck movements. Conclusions: Application of TENS with an IR lamp is useful and practical in home treatment of patients with cervical symptoms of AS. Also, we must not forget kinesitherapy and NSAIDs, which are a necessary part of treatment.